基于β-葡萄糖的超吸收性水凝作为胃肠外骨架,增强腹感并干扰脂肪水解
Yiming Jiang1, Shiqi Zhang1, Linfan Pan2
1State Key Laboratory of Food Science and Resources, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, PR China.
International journal of biological macromolecules
|June 30, 2024
概括
一种新的水凝有效地减少了脂肪的吸收和摄入量,有助于体重控制. 这种可摄入的物质有助于控制食欲和恢复脂质代谢平衡,为代谢障碍提供非侵入性解决方案.
科学领域:
- 生物材料科学 生物材料科学
- 营养科学 营养科学
- 胃肠病学 胃肠病学
背景情况:
- 在西方饮食中常见的过度脂肪摄入导致肥胖和代谢障碍.
- 脂肪酸是必不可少的,但它们的过度消费会给健康带来风险.
- 当前的减肥策略往往缺乏非侵入性,有效的解决方案.
研究的目的:
- 开发和评估一种用于体重控制的新型,每日可摄入的水凝.
- 为了研究水凝对食欲,食物摄入量和脂质代谢的影响.
- 评估水凝作为一种非侵入性胃肠道装置的潜力.
主要方法:
- 制造一个与酸交叉连接的β-葡萄糖和碳素甲基纤维素水凝 (βC-MA).
- 在脱离离子水中评估水凝膨胀动力学.
- 在体外和体内研究评估对脂肪消化,吸收和血清甘油三水平的影响.
主要成果:
- βC-MA水凝显示出快速胀 (1分钟24倍,1小时176倍).
- 水凝延长了胃缩和增加了腹信号,减少了食物摄入量.
- 有效抑制脂肪水解 (~50%的自由脂肪酸减少) 和降低血清甘油三水平 (22.2%).
结论:
- 作为一种非侵入性的体重管理工具,βC-MA水凝显示出前景.
- 水凝有效降低脂肪的吸收和摄入量,有助于新陈代谢调节.
- 进一步的研究可以确定βC-MA水凝作为治疗肥胖和相关疾病的治疗策略.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
203
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
203
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K


